LAUSR

COVID-19 pandemic is the biggest global crisis. The frequent mutations in coronavirus to generate new mutants is of major concern. The pathophysiology of SARS-CoV-2 infection has been well studied to find out suitable molecular targets and candidate drugs for effective treatment. FDA-recommended etiotropic therapies are currently followed along with mass vaccination. The drug delivery system and the route of administration have a great role to enhance the efficacy of therapeutic agents and vaccines. Since COVID-19 primarily infects the lungs in the affected individuals, pulmonary administration may be the best possible route for the treatment of COVID-19. Liposomes, solid lipid nanoparticles, polymeric nanoparticles, porous microsphere, dendrimers, and nanoparticles encapsulated microparticles are the most suitable drug delivery systems for targeted drug delivery. The solubility, permeability, chemical stability, and biodegradability of drug molecules are the key factors for the right selection of suitable nanocarriers. The application of nanotechnology has been instrumental in the successful development of mRNA, DNA and subunit vaccines, as well as the delivery of COVID-19 therapeutic agents.